Back to Search
Start Over
Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy.
- Source :
-
Neurological research and practice [Neurol Res Pract] 2022 Feb 08; Vol. 4 (1), pp. 6. Date of Electronic Publication: 2022 Feb 08. - Publication Year :
- 2022
-
Abstract
- This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.<br /> (© 2022. The Author(s).)
Details
- Language :
- English
- ISSN :
- 2524-3489
- Volume :
- 4
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Neurological research and practice
- Publication Type :
- Editorial & Opinion
- Accession number :
- 35130960
- Full Text :
- https://doi.org/10.1186/s42466-022-00172-1